Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cogn Affect Behav Neurosci ; 24(2): 351-367, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38253774

RESUMO

The rapid serial visual presentation (RSVP) task and continuous performance tasks (CPT) are used to assess attentional impairments in patients with psychiatric and neurological conditions. This study developed a novel touchscreen task for rats based on the structure of a human RSVP task and used pharmacological manipulations to investigate their effects on different performance measures. Normal animals were trained to respond to a target image and withhold responding to distractor images presented within a continuous sequence. In a second version of the task, a false-alarm image was included, so performance could be assessed relative to two types of nontarget distractors. The effects of acute administration of stimulant and nonstimulant treatments for ADHD (amphetamine and atomoxetine) were tested in both tasks. Methylphenidate, ketamine, and nicotine were tested in the first task only. Amphetamine made animals more impulsive and decreased overall accuracy but increased accuracy when the target was presented early in the image sequence. Atomoxetine improved accuracy overall with a specific reduction in false-alarm responses and a shift in the attentional curve reflecting improved accuracy for targets later in the image sequence. However, atomoxetine also slowed responding and increased omissions. Ketamine, nicotine, and methylphenidate had no specific effects at the doses tested. These results suggest that stimulant versus nonstimulant treatments have different effects on attention and impulsive behaviour in this rat version of an RSVP task. These results also suggest that RSVP-like tasks have the potential to be used to study attention in rodents.


Assuntos
Anfetamina , Cloridrato de Atomoxetina , Atenção , Estimulantes do Sistema Nervoso Central , Ketamina , Metilfenidato , Nicotina , Animais , Estimulantes do Sistema Nervoso Central/farmacologia , Estimulantes do Sistema Nervoso Central/administração & dosagem , Cloridrato de Atomoxetina/farmacologia , Cloridrato de Atomoxetina/administração & dosagem , Atenção/efeitos dos fármacos , Atenção/fisiologia , Masculino , Ratos , Metilfenidato/farmacologia , Metilfenidato/administração & dosagem , Nicotina/farmacologia , Nicotina/administração & dosagem , Anfetamina/farmacologia , Anfetamina/administração & dosagem , Ketamina/farmacologia , Ketamina/administração & dosagem , Estimulação Luminosa/métodos , Inibidores da Captação Adrenérgica/farmacologia , Inibidores da Captação Adrenérgica/administração & dosagem , Aprendizagem Seriada/efeitos dos fármacos , Aprendizagem Seriada/fisiologia , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Percepção Visual/efeitos dos fármacos , Percepção Visual/fisiologia , Ratos Sprague-Dawley
2.
Behav Brain Res ; 372: 112051, 2019 10 17.
Artigo em Inglês | MEDLINE | ID: mdl-31276704

RESUMO

Major depressive disorder (MDD) is one of the leading global causes of disability. Symptoms of MDD can vary person to person, and current treatments often fail to alleviate the poor quality of life that patients experience. One of the two core diagnostic criteria for MDD is the loss of interest in previously pleasurable activities, which suggests a link between the disease aetiology and reward processing. Cognitive impairments are also common in patients with MDD, and more recently, emotional processing deficits known as affective biases have been recognised as a key feature of the disorder. Studies in animals have found similar affective biases related to reward. In this review we consider these affective biases in the context of other reward-related deficits and examine how affective biases associated with learning and memory may interact with the wider behavioural symptoms seen in MDD. We discuss recent developments in how analogues of affective biases and other aspects of reward processing can be assessed in rodents, as well as how these behaviours are influenced in models of MDD. We subsequently discuss evidence for the neurobiological mechanisms contributing to one or more reward-related deficits in preclinical models of MDD, identified using these behavioural assays. We consider how the relationships between these selective behavioural assays and the neurobiological mechanisms for affective bias and reward processing could be used to identify potential treatment strategies.


Assuntos
Sintomas Afetivos/fisiopatologia , Transtorno Depressivo Maior/fisiopatologia , Transtornos Mentais/fisiopatologia , Animais , Viés , Cognição/fisiologia , Transtorno Depressivo Maior/diagnóstico , Modelos Animais de Doenças , Emoções/fisiologia , Humanos , Aprendizagem , Memória , Transtornos Mentais/metabolismo , Camundongos , Qualidade de Vida , Ratos , Recompensa
3.
Psychopharmacology (Berl) ; 234(2): 255-266, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-27744551

RESUMO

RATIONALE: Atomoxetine is a noradrenaline re-uptake inhibitor licensed for the treatment of adult and childhood attention deficit hyperactivity disorder. Although atomoxetine has established efficacy, the mechanisms which mediate its effects are not well understood. OBJECTIVES: In this study, we investigated the role of cortical versus sub-cortical noradrenaline by using focal dopamine beta hydroxylase-saporin-induced lesions, to the prefrontal cortex (n = 16) or nucleus accumbens shell (n = 18). METHODS: Healthy animals were tested by using the forced-choice serial reaction time task to assess the impact of the lesion on baseline performance and the response to atomoxetine and the psychostimulant amphetamine. RESULTS: We observed attenuation in the efficacy of atomoxetine in animals with lesions to the nucleus accumbens shell, but not the prefrontal cortex. Amphetamine-induced increases in premature responses were potentiated in animals with lesions to the prefrontal cortex, but not the nucleus accumbens shell. CONCLUSIONS: These data suggest that noradrenaline in the nucleus accumbens shell plays an important role in the effects of atomoxetine. Under these conditions, prefrontal cortex noradrenaline did not appear to contribute to atomoxetine's effects suggesting a lack of cortical-mediated "top-down" modulation. Noradrenaline in the prefrontal cortex appears to contribute to the modulation of impulsive responding in amphetamine-treated animals, with a loss of noradrenaline associated with potentiation of its effects. These data demonstrate a potential dissociation between cortical and sub-cortical noradrenergic mechanisms and impulse control in terms of the actions of atomoxetine and amphetamine.


Assuntos
Comportamento Impulsivo/fisiologia , Norepinefrina/fisiologia , Núcleo Accumbens/fisiologia , Córtex Pré-Frontal/fisiologia , Inibidores da Captação Adrenérgica/farmacologia , Animais , Cloridrato de Atomoxetina/farmacologia , Comportamento de Escolha/efeitos dos fármacos , Comportamento de Escolha/fisiologia , Comportamento Impulsivo/efeitos dos fármacos , Masculino , Norepinefrina/farmacologia , Núcleo Accumbens/efeitos dos fármacos , Córtex Pré-Frontal/efeitos dos fármacos , Propilaminas/farmacologia , Ratos
4.
J Neurosci ; 36(18): 4930-9, 2016 05 04.
Artigo em Inglês | MEDLINE | ID: mdl-27147648

RESUMO

UNLABELLED: Finding effective cognitive enhancers is a major health challenge; however, modulating glutamatergic neurotransmission has the potential to enhance performance in recognition memory tasks. Previous studies using glutamate receptor antagonists have revealed that the medial prefrontal cortex (mPFC) plays a central role in associative recognition memory. The present study investigates short-term recognition memory using optogenetics to target glutamatergic neurons within the rodent mPFC specifically. Selective stimulation of glutamatergic neurons during the online maintenance of information enhanced associative recognition memory in normal animals. This cognitive enhancing effect was replicated by local infusions of the AMPAkine CX516, but not CX546, which differ in their effects on EPSPs. This suggests that enhancing the amplitude, but not the duration, of excitatory synaptic currents improves memory performance. Increasing glutamate release through infusions of the mGluR7 presynaptic receptor antagonist MMPIP had no effect on performance. SIGNIFICANCE STATEMENT: These results provide new mechanistic information that could guide the targeting of future cognitive enhancers. Our work suggests that improved associative-recognition memory can be achieved by enhancing endogenous glutamatergic neuronal activity selectively using an optogenetic approach. We build on these observations to recapitulate this effect using drug treatments that enhance the amplitude of EPSPs; however, drugs that alter the duration of the EPSP or increase glutamate release lack efficacy. This suggests that both neural and temporal specificity are needed to achieve cognitive enhancement.


Assuntos
Glutamatos/fisiologia , Memória/fisiologia , Neurônios/fisiologia , Optogenética , Córtex Pré-Frontal/fisiologia , Reconhecimento Psicológico/fisiologia , Animais , Dioxóis/farmacologia , Potenciais Pós-Sinápticos Excitadores/efeitos dos fármacos , Masculino , Memória de Curto Prazo/fisiologia , Piperidinas/farmacologia , Proteínas Proto-Oncogênicas c-fos/fisiologia , Desempenho Psicomotor/fisiologia , Piridonas/farmacologia , Ratos , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Receptores de Glutamato Metabotrópico/fisiologia
5.
PLoS One ; 9(12): e115374, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25526617

RESUMO

The 5-choice serial reaction time task (5CSRTT) has been widely used to study attention and impulse control in rodents. In order to mimic cognitive impairments in psychiatry, one approach has been to use acute administration of NMDA antagonists. This disruption in glutamatergic transmission leads to impairments in accuracy, omissions, and premature responses although findings have been inconsistent. In this study, we further investigated glutamatergic mechanisms using a novel version of the 5CSRTT, which we have previously shown to be more sensitive to cognitive enhancers. We first investigated the effects of systemic treatment with NMDA antagonists. We also carried out a preliminary investigation using targeted medial prefrontal cortex infusions of a NMDA antagonist (MK801), mGluR2/3 antagonist (LY341495), and mGluR7 negative allosteric modulator (MMPIP). Acute systemic administration of the different NMDA antagonists had no specific effects on accuracy. At higher doses PCP, ketamine, and memantine, increased omissions and affected other measures suggesting a general disruption in task performance. Only MK801 increased premature responses, and reduced omissions at lower doses suggesting stimulant like effects. None of the NMDA antagonists affected accuracy or any other measures when tested using a short stimulus challenge. Infusions of MK801 had no effect on accuracy but increased premature responses following infralimbic, but not prelimbic infusion. LY341495 had no effects in either brain region but a decrease in accuracy was observed following prelimbic infusion of MMPIP. Contrary to our hypothesis, disruptions to glutamate transmission using NMDA antagonists did not induce any clear deficits in accuracy in this modified version of the 5CSRTT. We also found that the profile of effects for MK801 differed from those observed with PCP, ketamine, and memantine. The effects of MK801 in the infralimbic cortex add to the literature indicating this brain region and glutamate play an important role in impulse control.


Assuntos
Aminoácidos/administração & dosagem , Atenção/efeitos dos fármacos , Maleato de Dizocilpina/administração & dosagem , Antagonistas de Aminoácidos Excitatórios/administração & dosagem , Comportamento Impulsivo/efeitos dos fármacos , Tempo de Reação/efeitos dos fármacos , Xantenos/administração & dosagem , Aminoácidos/farmacologia , Animais , Modelos Animais de Doenças , Maleato de Dizocilpina/farmacologia , Relação Dose-Resposta a Droga , Antagonistas de Aminoácidos Excitatórios/farmacologia , Masculino , N-Metilaspartato/antagonistas & inibidores , Córtex Pré-Frontal/efeitos dos fármacos , Ratos , Xantenos/farmacologia
6.
Stem Cells ; 30(10): 2330-41, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22887880

RESUMO

The dystrophin-associated glycoprotein complex (DGC) is found at the muscle fiber sarcolemma and forms an essential structural link between the basal lamina and internal cytoskeleton. In a set of muscular dystrophies known as the dystroglycanopathies, hypoglycosylation of the DGC component α-dystroglycan results in reduced binding to basal lamina components, a loss in structural stability, and repeated cycles of muscle fiber degeneration and regeneration. The satellite cells are the key stem cells responsible for muscle repair and reside between the basal lamina and sarcolemma. In this study, we aimed to determine whether pathological changes associated with the dystroglycanopathies affect satellite cell function. In the Large(myd) mouse dystroglycanopathy model, satellite cells are present in significantly greater numbers but display reduced proliferation on their native muscle fibers in vitro, compared with wild type. However, when removed from their fiber, proliferation in culture is restored to that of wild type. Immunohistochemical analysis of Large(myd) muscle reveals alterations to the basal lamina and interstitium, including marked disorganization of laminin, upregulation of fibronectin and collagens. Proliferation and differentiation of wild-type satellite cells is impaired when cultured on substrates such as collagen and fibronectin, compared with laminins. When engrafted into irradiated tibialis anterior muscles of mdx-nude mice, wild-type satellite cells expanded on laminin contribute significantly more to muscle regeneration than those expanded on fibronectin. These results suggest that defects in α-dystroglycan glycosylation are associated with an alteration in the satellite cell niche, and that regenerative potential in the dystroglycanopathies may be perturbed.


Assuntos
Membrana Basal/metabolismo , Distroglicanas/metabolismo , Fibras Musculares Esqueléticas/metabolismo , Distrofia Muscular Animal/metabolismo , Sarcolema/metabolismo , Células Satélites de Músculo Esquelético/metabolismo , Animais , Membrana Basal/patologia , Diferenciação Celular , Proliferação de Células , Colágeno/química , Colágeno/metabolismo , Modelos Animais de Doenças , Fibronectinas/química , Fibronectinas/metabolismo , Glicosilação , Humanos , Laminina/química , Laminina/metabolismo , Camundongos , Fibras Musculares Esqueléticas/patologia , Músculo Esquelético/patologia , Distrofia Muscular Animal/patologia , Ligação Proteica , Sarcolema/patologia , Células Satélites de Músculo Esquelético/citologia , Células Satélites de Músculo Esquelético/transplante
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...